Q-omics provides the consensus-scored MAPKAPK3 profile across patient tissues and cancer cell-line models. MAPKAPK3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MAPKAPK3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, MAPKAPK3 protein abundance shows 24,394 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where MAPKAPK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPKAPK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPKAPK3 survival associations across molecular data types. MAPKAPK3 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPKAPK3 RNA expression–survival associations across cancer types. High MAPKAPK3 expression shows unfavorable associations in LGG, but favorable associations in KIRP, UVM, KIRC, LUAD and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MAPKAPK3 RNA expression.
This table summarizes MAPKAPK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAPKAPK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPKAPK3 shows lower tumor expression in HNSC, LUSC and KIRC and higher tumor expression in COAD, THCA and LIHC. The HNSC box plot shows higher MAPKAPK3 RNA expression in normal versus tumor tissue (log2 FC = −1.159, t-test p < 0.001).
This table shows molecular features associated with MAPKAPK3 in patient tissues and cancer cell lines. In patient samples, MAPKAPK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPKAPK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
